Imaging Diagnostic Systems (IMDS) 10-Q 15 May 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2023	May 15, 2023
Document Information Line Items
Entity Registrant Name	IMAGING DIAGNOSTIC SYSTEMS INC /FL/
Document Type	10-Q
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		123,156,941
Amendment Flag	false
Entity Central Index Key	0000790652
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-26028
Entity Incorporation, State or Country Code	FL
Entity Tax Identification Number	22-2671269
Entity Address, Address Line One	618 E South St
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	Orlando
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32801
City Area Code	(954)
Local Phone Number	581-9800
Entity Interactive Data Current	Yes

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Current assets:
Cash	$ 123	$ 613
Prepaid expenses and deposits	11,783	11,989
Total current assets	11,906	12,602
Property and equipment, net
Total assets	11,906	12,602
Current liabilities:
Accounts payable and accrued expenses	910,920	767,317
Accrued payroll taxes and penalties	314,019	314,019
Promissory notes, related party	753,954	671,276
PPP loan payable	72,930	72,930
Total current liabilities	2,051,823	1,825,542
Total liabilities	2,051,823	1,825,542
Commitment and Contingencies (Note 17)
Temporary equity
Convertible Preferred Stock -Series L	447,451	433,939
Total temporary equity	447,451	433,939
Stockholders’ Deficit:
Preferred stock, no par , 2,000,000 authorized Convertible preferred stock, Series M, 600 designated 0 shares issued and outstanding at March 31, 2023 and June 30, 2022
Common stock, no par value, 500,000,000 authorized , 123,156,941 shares issued and outstanding March 31, 2023 and June 30, 2022	133,296,816	133,236,117
Accumulated Deficit	(135,784,184)	(135,482,996)
Total stockholders’ deficit	(2,487,368)	(2,246,879)
Total liabilities and stockholders’ deficit	$ 11,906	$ 12,602

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2023	Jun. 30, 2022
Preferred stock, shares par value (in Dollars per share)
Preferred stock, shares authorized	2,000,000	2,000,000
Common stock, shares par value (in Dollars per share)
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	123,156,941	123,156,941
Common stock, shares outstanding	123,156,941	123,156,941
Series M
Preferred stock, designated	600	600
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Total Revenue
Cost of Sales
Gross Profit
Operating Expenses:
General and administrative	15,223	13,873	76,983	73,547
Sales and marketing	124	314	630	551
Consulting expenses (including share-based compensation)	5,888	171,479	148,704	334,178
Total Operating Expenses	21,235	185,666	226,317	408,276
Operating Loss	(21,235)	(185,666)	(226,317)	(408,276)
Other Income (expense)
Interest expense	(20,155)	(20,215)	(61,359)	(61,391)
Total Other Expense	(20,155)	(20,215)	(61,359)	(61,391)
Net Loss	(41,390)	(205,881)	(287,676)	(469,667)
Preferred Stock Dividends	(4,438)	(4,438)	(13,512)	(13,512)
Net Loss Available to Common Stockholders	$ (45,828)	$ (210,319)	$ (301,188)	$ (483,179)
Net Loss per common share:
Basic and diluted (in Dollars per share)
Weighted average number of common shares outstanding:
Basic and diluted (in Shares)	123,156,941	123,156,941	123,156,941	123,156,941

Statements of Operations (Una_2

Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net Loss per common share diluted
Weighted average number of common shares outstanding diluted	123,156,941	123,156,941	123,156,941	123,156,941

Statements of Changes in Stockh

Statements of Changes in Stockholders’ Deficit (Unaudited) - USD ($)	Common Stock	Accumulated Deficit	Total
Balance at Jun. 30, 2021	$ 132,974,686	$ (134,817,667)	$ (1,842,981)
Balance (in Shares) at Jun. 30, 2021	123,156,941
Cummulative Dividend on Series L CV Preferred		(4,537)	(4,537)
Net loss		(111,984)	(111,984)
Balance at Sep. 30, 2021	$ 132,974,686	(134,934,188)	(1,959,502)
Balance (in Shares) at Sep. 30, 2021	123,156,941
Balance at Jun. 30, 2021	$ 132,974,686	(134,817,667)	(1,842,981)
Balance (in Shares) at Jun. 30, 2021	123,156,941
Net loss			(469,667)
Balance at Mar. 31, 2022	$ 133,155,864	(135,300,846)	(2,144,982)
Balance (in Shares) at Mar. 31, 2022	123,156,941
Balance at Sep. 30, 2021	$ 132,974,686	(134,934,188)	(1,959,502)
Balance (in Shares) at Sep. 30, 2021	123,156,941
Cummulative Dividend on Series L CV Preferred		(4,537)	(4,537)
Stock options expense	60,699		60,699
Net loss		(151,802)	(151,802)
Balance at Dec. 31, 2021	$ 133,035,385	(135,090,527)	(2,055,142)
Balance (in Shares) at Dec. 31, 2021	123,156,941
Cummulative Dividend on Series L CV Preferred		(4,438)	(4,438)
Stock options expense	120,479		120,479
Net loss		(205,881)	(205,881)
Balance at Mar. 31, 2022	$ 133,155,864	(135,300,846)	(2,144,982)
Balance (in Shares) at Mar. 31, 2022	123,156,941
Balance at Jun. 30, 2022	$ 133,236,117	(135,482,996)	(2,246,879)
Balance (in Shares) at Jun. 30, 2022	123,156,941
Cummulative Dividend on Series L CV Preferred		(4,537)	(4,537)
Net loss		(117,325)	(117,325)
Balance at Sep. 30, 2022	$ 133,236,117	(135,604,858)	(2,368,741)
Balance (in Shares) at Sep. 30, 2022	123,156,941
Balance at Jun. 30, 2022	$ 133,236,117	(135,482,996)	(2,246,879)
Balance (in Shares) at Jun. 30, 2022	123,156,941
Net loss			(287,676)
Balance at Mar. 31, 2023	$ 133,296,816	(135,784,184)	(2,487,368)
Balance (in Shares) at Mar. 31, 2023	123,156,941
Balance at Sep. 30, 2022	$ 133,236,117	(135,604,858)	(2,368,741)
Balance (in Shares) at Sep. 30, 2022	123,156,941
Cummulative Dividend on Series L CV Preferred		(4,537)	(4,537)
Stock options expense	60,699		60,699
Net loss		(128,961)	(128,961)
Balance at Dec. 31, 2022	$ 133,296,816	(135,738,356)	(2,441,540)
Balance (in Shares) at Dec. 31, 2022	123,156,941
Cummulative Dividend on Series L CV Preferred		(4,438)	(4,438)
Net loss		(41,390)	(41,390)
Balance at Mar. 31, 2023	$ 133,296,816	$ (135,784,184)	$ (2,487,368)
Balance (in Shares) at Mar. 31, 2023	123,156,941

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (287,676)	$ (469,667)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option expense	60,699	181,178
Changes in assets and liabilities:
Decrease in prepaid expenses and deposits	206	528
Increase in accounts payable and accrued expenses	147,272	212,718
Total adjustments	208,177	394,424
Net cash used in operating activities	(79,499)	(75,243)
Cash flows from financing activities:
Proceeds from promissory notes, related party	79,009	80,000
(Repayment) of Paycheck Protection Program Loan		(6,670)
Net cash provided by financing activities	79,009	73,330
Net (decrease) in cash	(490)	(1,913)
Cash at the beginning of year	613	2,473
Cash at end of the period	123	560
Supplemental Disclosure of cash flow information:
Cash paid for interest		1,497
Cash paid for taxes
Non-cash investing and financing activities:
Promissory notes issued in exchange for settlement of accounts payable	$ 3,669

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended
	Mar. 31, 2023
Organization and Nature of Business [Abstract]
ORGANIZATION AND NATURE OF BUSINESS	(1) ORGANIZATION AND NATURE OF BUSINESS Imaging Diagnostic Systems, Inc. (the “Company” or “IDSI”) is a medical technology company that has developed a new, non-invasive CT scanner called CTLM® that uses a laser beam in place of ionizing X-ray for breast imaging. This technology is called Diffuse Optical Tomography. The CTLM® will provide an adjunctive imaging modality to other methods of imaging the breast such as X-ray mammography, MRI and ultrasound. Since inception in December 1993 as a Florida corporation and subsequently its reverse merger with Alkan Corp., a New Jersey Corporation on April 14, 1994, we continued operations and changed our state of incorporation from New Jersey to Florida, effective July 1, 1995.

Going Concern and Management's

Going Concern and Management's Plans	9 Months Ended
	Mar. 31, 2023
Going Concern and Management's Plans Disclosure [Abstract]
GOING CONCERN AND MANAGEMENT’S PLANS	(2) GOING CONCERN AND MANAGEMENT’S PLANS The accompanying financial statements are prepared assuming the Company will continue as a going concern. As of March 31, 2023, the Company had an accumulated deficit of $135,784,184, a stockholders’ deficit of $2,487,368 and a working capital deficiency of $2,039,917. For the nine months ended March 31, 2023, net loss totaled $287,676. The net cash used in operating activities for the nine months ended March 31, 2023 totaled $79,499. These matters raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date these financial statements are issued. The ability of the Company to continue as a going concern is dependent upon generating sales and obtaining additional capital and financing. While the Company believes in the viability of its strategy to generate material sales volume and in its ability to raise additional funds, there can be no assurances to that effect. The Company received from the Chinese FDA (“CFDA”) marketing clearance for the CTLM® effective November 16, 2018 to November 15, 2023. However, there can be no assurance that we will obtain U.S. Food and Drug Administration (“FDA”) marketing or other new international marketing clearances, that the CTLM® will achieve market acceptance or that sufficient revenues will be generated from sales of the CTLM® in China or elsewhere to allow us to operate profitably. Since 2016, we have financed our operations through loans by Viable International Investments, LLC (“Viable”), our majority shareholder, and its affiliates and the private placement of common stock to Viable affiliates and independent Chinese investors. We do not have any formal financing arrangements with Viable and its affiliates; however, Viable has stated its intention to continue to provide financing of our operations consistent with past practice. While we believe that Viable and its affiliates will provide on commercially reasonable terms the funding we need until we achieve a positive cash flow from operations, there can be no assurance that we will receive such funding or that we will ever achieve profitability. If Viable fails to continue funding, the Company would be materially adversely affected and may have to cease operations due to a lack of funding. These matters affect the Company’s liquidity profile, and management’s plans in those regards are discussed in the paragraphs that follow. During fiscal year 2023, we anticipate that losses from operations will continue until we begin to generate revenues through the sales of CTLM® systems in China. These losses will be primarily due to an anticipated increase in marketing, manufacturing and operational expenses associated with the international commercialization of the CTLM®, expenses associated with FDA approval processes, and the costs associated with advanced product development activities. The Company’s next focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of its CTLM® Breast Imaging System through the FDA. The premarket approval (“PMA”) process for U.S. marketing clearance is expected to take longer than the Chinese process, and we intend to resume this effort after achieving successful marketing and sales of CTLM® systems in China. Our sales and marketing efforts in China have been significantly hindered by the ongoing COVID-19 pandemic, and therefore we do not expect revenue from China in the foreseeable future. No sales in other countries are expected in the foreseeable future, as we do not intend to pursue sales in other countries until after obtaining FDA marketing clearance, as to which there can be no assurance. In analyzing the regulatory path forward, timeline, and costs associated with the level of effort required to upgrade the Company’s Quality Management System (QMS), we have decided not to renew our CE mark (required for sales in the European Union) for this year and to consider reapplying in 2 to 3 years to avoid these regulatory fees. Similarly, we will maintain our Quality Management System to be compliant to ISO 13485:2016 but not certify to ISO 13485:2016 by Underwriters Laboratories (UL) which will allow us to avoid fees associated with certification, travel, and hosting audits. Maintaining our QMS to be ISO 13485:2016 compliant will allow us to quickly schedule an audit with UL and become ISO 13485 certified when necessary. On October 23, 2019, the Company entered into a consulting agreement (“the Agreement”) effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focused on improving the technical performance and image quality of IDSI’s Computed Tomography Laser Mammography (CTLM ® Xi’an IDI has been working with Yiling Hospital Management Group based in Beijing, China (“Yiling”) to evaluate CTLM®’s potential use and application. As of the date of this report, Xi’an IDI has loaned three CTLM® systems to Yiling and Yiling is at the stage of testing and data validation. It is important that the effectiveness of the image quality improvements be established before Xi’an IDI can resume their sales and marketing efforts in China. Once the Company has substantial revenues and cash flow, it believes it will be able to raise the necessary funding to allow the Company to move forward with its various R&D and regulatory initiatives that have been put on hold due to the COVID-19 pandemic. The Company’s ability to continue as a going concern and its future success are dependent upon its ability to raise additional capital in the near term to: (1) satisfy its current obligations, (2) continue its research and development efforts, and (3) successfully develop, market, and sell its products. Due to the difficulty of raising additional capital during the current COVID-19 crisis, the Company has been taking aggressive measures to reduce its operating costs in order to preserve cash. The Company’s ability to meet its cash flow requirements through fiscal 2023 and continue its development and commercialization efforts will be dependent on the length and severity of the COVID-19 crisis and the Company’s ability to secure additional funding. There can be no assurance that IDSI will generate sufficient revenue to provide positive cash flows from operations or that sufficient capital will be available, when required, to permit the Company to execute its plan of operations. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of presentation and use of estimates The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). The unaudited interim financial information furnished herein reflects all adjustments, consisting only of normal recurring items, which in the opinion of management are necessary to fairly state the Company’s financial position, results of operations and cash flows for the dates and periods presented and to make such information not misleading. The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal year ended June 30, 2022, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “Commission”) on October 4, 2022. The results of operations for the nine months ended March 31, 2023, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2023. (b) Revenue recognition As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue. The Company also receives royalties pursuant to a licensing relationship with Trifoil Imaging. Revenue is recognized in the reporting periods in which royalties are due to the Company. During the nine months ended March 31, 2023 and 2022, there was no income from royalties. (c) Allowance for doubtful accounts In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience. Our allowance for doubtful accounts was $850 as of March 31, 2023 and June 30, 2022. These amounts consist of other receivables that have been fully reserved. (d) Cash and cash equivalents Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2023 and June 30, 2022. (e) Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. March 31, 2023 and June 30, 2022, the Company did not have cash balances in excess of the federally insured limit. The Company did not have any revenue for the nine months ended March 31, 2023 and 2022. (f) Inventory Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of obsolete inventory. The Company maintains an allowance for obsolete inventory and generally makes inventory value adjustments against the allowance. (g) Property and equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred. (h) Research and development Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company’s CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device. (i) Net loss per share The Company relies on the guidance provided by ASC 260, (“Earnings per Share”), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive. The Company had 5,110,000 and 9,610,012 options vested as of March 31, 2023 and June 30, 2022, respectively and 1,095,290 and 1,595,290 options not yet vested as of March 31, 2023 and June 30, 2022, respectively. (j) Stock-based compensation In July 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard. The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. No stock options were granted during nine months ended March 31, 2023 and 2022. Stock options are being expensed pursuant to ASC 718. The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (16) Stock Options. (k) Long-lived assets The Company relies on the guidance provided by ASC 360 (“Property, Plant & Equipment”). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized. The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2023 and 2022. (l) Income taxes The Company accounts for income taxes pursuant to the provisions of ASC 740-10, “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2020 to 2022 are still potentially subject to audit by the taxing authorities. (m) Warranty reserve The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company’s experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company’s estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2023 or June 30, 2022. (n) Impact of recently issued accounting pronouncements Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption. (o) Fair Value of Financial Instruments The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company’s debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2023 and June 30, 2022, the aggregate fair value of the Company’s debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 (“Fair Value Measurements and Disclosures”). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Revenue

Revenue	9 Months Ended
	Mar. 31, 2023
Revenue [Abstract]
REVENUE	(4) REVENUE The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Sales taxes and other similar taxes are excluded from revenue. As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on its financial statements. The Company expects that the impact to net income of the new standard will be immaterial on an ongoing quarterly and annual basis. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Company had no revenues during the nine months ended March 31, 2023 and 2022.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	(5) RELATED PARTY TRANSACTIONS Related party revenues On March 22, 2018, the Board of Directors approved the execution of two agreements with Xi’an of China, an affiliated Company of IDSI. The agreements are a Know How Transfer Contract and a CTLM Know How Confidentiality Agreement. The contract, having a term of 20 years, stipulates that Xi’an will pay IDSI a know how transfer fee of 25% of revenue for CTLM product sales in their territory. There were no such sales during the nine months ended March 31, 2023 and 2022. Related party fees Erhfort, LLC earned a consulting fee of $51,000 for the nine-month period ended March 31, 2023 and $76,500 for the nine-month period ending March 31, 2022. Erhfort, LLC regularly reviews the Company’s operations and reports to IDSI’s CEO who lives in China. Erhfort, LLC is a related party because it owns Company common stock directly and indirectly. David Fong, who served as the Company’s CFO through August 10, 2022 and as a consultant on an as needed basis thereafter, earned consulting fees of $32,545 for the nine-month period ended March 31, 2023 and $76,500 for the nine-month period ended March 31, 2022. These fees were assigned to his affiliated business, Fong & Associates, LLC. Related party payables and accrued expenses As of March 31, 2023 and June 30, 2022, the amount of interest on related party notes due to Erhfort, LLC, which is included in accounts payable, is $219,814 and $161,260, respectively. As of March 31, 2023 and June 30, 2022, the amount of consulting fees due to Ehrfort, LLC, which is included in accounts payable, is $204,000 and $153,000, respectively. As March 31, 2023 and June 30, 2022, the amount of consulting fees due to Fong & Associates, LLC, which is included in accounts payable and accrued expenses, is $318,545 and $286,000, respectively. As of March 31, 2023 and June 30, 2022, the amount of reimbursable expenses due to Fong & Associates, LLC, which is included in accounts payable, is $2,808 and $839, respectively. As of March 31, 2023 and June 30, 2022, the amount of interest on related party notes due to JM One Holdings, LLC, which is included in accrued expenses, is $11,112 and $8,860, respectively. JM One Holdings, LLC is an entity affiliated with David Fong. Related party debt As of March 31, 2023 and June 30, 2022, the amount in promissory notes due to related parties are $753,954 and $671,276, respectively (See Note 12).

Royalty Receivable

Royalty Receivable	9 Months Ended
	Mar. 31, 2023
Royalty Receivable [Abstract]
ROYALTY RECEIVABLE	(6) ROYALTY RECEIVABLE On June 16, 2006, the Company entered into a Royalty Agreement with Bioscan Inc. whereby the Company established a licensing relationship with Bioscan which granted Bioscan an exclusive sublicensable, royalty-bearing license to make, use, offer for sale, import and otherwise develop and commercialize products in its territory. Bioscan Inc. was subsequently purchased by TriFoil Imaging. During the nine months ended March 31, 2023 and 2022, there was no royalty income. As of March 31, 2023 and June 30, 2022, the Company had royalty receivable balances of $0.

Inventories

Inventories	9 Months Ended
	Mar. 31, 2023
Inventories Disclosure [Abstract]
INVENTORIES	(7) INVENTORIES Inventories consisted of the following: March 31, June 30, Raw materials consisting of purchased parts, components and supplies $ 92,587 $ 92,587 Finished goods 7,500 7,500 Total Inventory $ 100,087 $ 100,087 Allowance for Obsolete Inventory (100,087 ) (100,087 ) Net Inventory $ - $ - Due to the age of the inventory, lack of demand for parts and lack of sales the Company reserved for all inventory during the year ended June 30, 2017. The Company is not carrying any inventory purchased after June 30, 2017 and has booked an allowance for the entire value of its inventory.

Prepaid Expenses and Deposits

Prepaid Expenses and Deposits	9 Months Ended
	Mar. 31, 2023
Prepaid Expenses and Deposits Disclosure [Abstract]
PREPAID EXPENSES AND DEPOSITS	(8) PREPAID EXPENSES AND DEPOSITS The following is a summary of prepaid expenses: March 31, June 30, Prepaid Software $ - $ 206 Rent Security Deposits 1,783 1,783 Consulting Retainers 10,000 10,000 Total Prepaid expenses and Deposits $ 11,783 $ 11,989

Property and Equipment

Property and Equipment	9 Months Ended
	Mar. 31, 2023
Property and Equipment Disclosure [Abstract]
PROPERTY AND EQUIPMENT	(9) PROPERTY AND EQUIPMENT The following is a summary of property and equipment, less accumulated depreciation: March 31, June 30, Useful life Computers and Equipment $ 12,612 $ 12,612 5 years Third Party Software 10,291 10,291 5 years Clinical Equipment 15,000 15,000 5 years Total Property & Equipment $ 37,903 $ 37,903 Less: accumulated depreciation (37,903 ) (37,903 ) Total Property & Equipment - Net $ - $ - Depreciation expense for the nine months ended March 31, 2023 and 2022 was $0.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Mar. 31, 2023
Accounts Payable and Accrued Expenses [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	(10) ACCOUNTS PAYABLE AND ACCRUED EXPENSES As of March 31, 2023 and June 30, 2022, accounts payable and accrued expenses totaled $910,920 and $767,317 respectively, which consists of accounts payable of $898,468 and $758,171 and other accrued expenses of $12,452 and $9,146, respectively.

Accrued Payroll Taxes and Penal

Accrued Payroll Taxes and Penalties	9 Months Ended
	Mar. 31, 2023
Accrued Payroll Taxes and Penalties [Abstract]
ACCRUED PAYROLL TAXES AND PENALTIES	(11) ACCRUED PAYROLL TAXES AND PENALTIES As of March 31, 2023 and June 30, 2022, the Company owed the IRS $314,019. Accrued payroll taxes represent outstanding interest and penalties based on prior management’s failure to pay payroll taxes commencing with the quarter ending March 31, 2010. As part of new management’s restructuring plan, the Company received funds from an accredited investor to be able to make a payment to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting penalty and interest abatement. The amount due at March 31, 2023 of $314,019 represents the interest and penalties. The Company has formally asked the IRS to abate all remaining interest and penalties of $314,019. The Company had a telephone conference on April 18, 2019 with the office of appeals and is waiting for further communications from the appeals officer. As of March 31, 2023, the Company’s tax counsel is in the process of reviewing recent IRS correspondence to determine appeals status and will work towards final resolutions with the IRS on all outstanding liabilities. The Company has decided to wait until all resolutions are final before making any adjustments to the balance of $314,019 owed to the IRS.

Promissory Notes _ Related Part

Promissory Notes – Related Party	9 Months Ended
	Mar. 31, 2023
Promissory Notes – Related Party [Abstract]
PROMISSORY NOTES – RELATED PARTY	(12) PROMISSORY NOTES – RELATED PARTY The following table is a summary of the outstanding note balances as of March 31, 2023 and June 30, 2022. Noteholder Interest Maturity March 31, June 30, Related Party Notes: Erhfort, LLC 15 % 6/30/23 $ 100,000 $ 100,000 Erhfort, LLC 15 % 6/30/23 100,000 100,000 JM One Holdings, LLC 15 % 6/30/23 20,000 20,000 Erhfort, LLC 15 % 6/30/23 100,000 100,000 Erhfort, LLC 15 % 6/30/23 100,000 100,000 Erhfort, LLC 15 % 6/30/23 100,000 100,000 Erhfort, LLC 15 % 6/30/23 10,000 10,000 Erhfort, LLC 15 % 6/30/23 10,000 10,000 Erhfort, LLC 0 % On Demand 2,260 - Erhfort, LLC 0 % On Demand 3,669 - Viable International Investments, LLC 0 % On Demand 7,865 7,865 Viable International Investments, LLC 0 % On Demand 5,000 5,000 Viable International Investments, LLC 0 % On Demand 5,000 5,000 Viable International Investments, LLC 0 % On Demand 5,000 5,000 Viable International Investments, LLC 0 % On Demand 5,000 5,000 Viable International Investments, LLC 0 % On Demand 3,000 3,000 Viable International Investments, LLC 0 % On Demand 15,000 15,000 Viable International Investments, LLC 0 % On Demand 30,000 30,000 Viable International Investments, LLC 0 % On Demand 10,000 10,000 Viable International Investments, LLC 0 % On Demand 10,000 10,000 Viable International Investments, LLC 0 % On Demand 10,000 10,000 Viable International Investments, LLC 0 % On Demand 5,000 5,000 Viable International Investments, LLC 0 % On Demand 10,000 10,000 Viable International Investments, LLC 0 % On Demand 8,847 - Viable International Investments, LLC 0 % On Demand 12,768 - Viable International Investments, LLC 0 % On Demand 9,988 - Viable International Investments, LLC 0 % On Demand 7,968 - Viable International Investments, LLC 0 % On Demand 6,968 - Viable International Investments, LLC 0 % On Demand 7,786 - Viable International Investments, LLC 0 % On Demand 5,368 - Viable International Investments, LLC 0 % On Demand 5,488 - Viable International Investments, LLC 0 % On Demand 11,568 - Xi’an IDI 0 % On Demand 10,411 10,411 Total Related Party Notes $ 753,954 $ 671,276 Erhfort, LLC and Viable International Investments, LLC own Company common stock directly and indirectly. JM One Holdings, LLC is an entity affiliated with the Company’s former CFO. Hence, these debts are considered related party debt. Xi’an IDI is affiliated with IDSI due to a licensing agreement. During the nine months ended March 31, 2023, the Company received loan proceeds of $76,749 from Viable International Investments, LLC and $2,260 from Erhfort, LLC with an annual interest rate of 0%. The Company also converted $3,669 of accounts payables into a loan from Erhfort, LLC with an annual interest rate of 0%. During the nine months ended March 31, 2022, the Company received loan proceeds of $80,000 from Viable International Investments, LLC with an annual interest rate of 0%. On March 31, 2023, the maturity dates of the loans that were due to mature on March 31, 2023 were extended to June 30, 2023. The extension of the maturity dates is a modification of the loans, and not accounted for as gain or loss extinguishments.

Long-Term Debt

Long-Term Debt	9 Months Ended
	Mar. 31, 2023
Long-Term Debt [Abstract]
LONG-TERM DEBT	(13) LONG-TERM DEBT The following table is a summary of the outstanding loan balances as of March 31, 2023 and June 30, 2022. Noteholder Interest Maturity March 31, June 30, Truist Bank 1 % In Default $ 72,930 $ 72,930 Total Debt 72,930 72,930 Current Portion of Debt (72,930 ) (72,930 ) Total Long-term Debt $ - $ - On May 9, 2020, the Company entered into a loan with Truist Bank, a lender pursuant to the Paycheck Protection Program of the CARES Act as administered by the SBA in the amount of $79,600. The loan, in the form of a promissory note, had an original maturity date of May 1, 2025. No additional collateral or guarantees were provided by the Company for the loan. The PPP loan provides for customary events of default. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, rent payments, mortgage interest and covered utilities during the 24-week period beginning on the date of loan disbursement. The Company is required to repay the entire amount of outstanding principal, along with accrued interest, as the Company is not eligible for forgiveness. The Company began to make payments, beginning October 2021, including interest accruing at an annual interest rate of 1.0% beginning on the date of disbursement. On May 17, 2022, the Company received a default and demand letter from Truist Bank in regards to the PPP loan due to non-payment. As such the remaining balance of the PPP loan became due immediately. As of March 31, 2023 and June 30, 2022, the Company reported an accrued interest balance related to the PPP Loan of $740 and $186, respectively. The accrued interest is included in accounts payable and accrued expenses on our balance sheets.

Convertible Preferred Stock

Convertible Preferred Stock	9 Months Ended
	Mar. 31, 2023
Convertible Preferred Stock [Abstract]
CONVERTIBLE PREFERRED STOCK	(14) CONVERTIBLE PREFERRED STOCK The following schedule reflects the number of shares of preferred stock that have been issued, converted and are outstanding as of March 31, 2023: Security Date Issued No. of Amount Date of No. of Amount Balance Series L Cv Pfd 3/31/2010 35 $ 350,000 1/6/2011 15 $ 150,000 $ 200,000 Dividends 247,451 Total redemption value $ 447,451 Total Series M Cv Pfd Various 600 $ 6,000,000 1/6/2011 600 $ 6,000,000 $ -0- Dividends -0- Total redemption value $ -0- Series L Convertible Preferred Stock On March 31, 2010, a private investor converted a $350,000 short-term promissory note into 35 shares of Series L Convertible Preferred Stock. The original purchase price/stated value is $10,000 per share and dividends accrue at an annual rate of 9%. The preferred stock is convertible into 474 shares of common stock for each share of preferred stock. On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time. At March 31, 2023 and June 30, 2022, the balance of cumulative dividends owed to the investor which is included in redemption value was $247,450 and $233,939, respectively. The total presented on the balance sheet as temporary equity is $447,451 as of March 31, 2023 and $433,939 as of June 30, 2022. Series M Convertible Preferred Stock The Company had previously sold 600 Series M Convertible Preferred Stock to Viable International Investments, LLC, a Florida limited liability company, (“Viable”). Each share of the Series M Preferred Stock was convertible into 147,283 shares of Common Stock. In the event of a liquidation, the holders of the Series M Preferred Stock would have been entitled to receive, prior to any distribution of assets to holders of Common Stock or other class of capital stock or other equity securities of the Corporation, $10,000 per share of Series M Preferred Stock held plus accrued but unpaid dividends. The holders of the Series M Preferred Stock would have had identical voting rights as any holder of Common Stock and would have voted together, not as separate classes. The original purchase price/stated value of each share of Series M Preferred Stock was $10,000 and Viable was be entitled to receive cumulative dividends at the fixed rate of 9% of the stated value per share per annum. On November 21, 2017, Viable converted 3 shares of its Series M Preferred Stock to 441,878 shares of restricted common stock. On April 18, 2017, Viable converted 6 shares of its Series M Preferred Stock to 883,696 shares of restricted common stock, and on August 7, 2018, Viable converted its remaining 591 shares of Series M Preferred Stock into 87,044,089 shares of restricted common stock. As of March 31, 2023 and June 30, 2022, the balance of Series M Preferred Stock was $0.

Common Stock

Common Stock	9 Months Ended
	Mar. 31, 2023
Common Stock [Abstract]
COMMON STOCK	(15) COMMON STOCK The Company has 500,000,000 of common shares no par value authorized and 2,000,000 of no The Company did not issue any shares of common or preferred stock during the nine months ended March 31, 2023 and 2022.

Stock Options

Stock Options	9 Months Ended
	Mar. 31, 2023
Stock Options [Abstract]
STOCK OPTIONS	(16) STOCK OPTIONS On December 4, 2016, the Board of Directors adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”) which was subsequently approved and adopted by majority written consent in lieu of an annual meeting. The purpose of the 2016 Plan is to encourage and enable the officers, employees, directors and other key persons (including consultants) of the Company, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company. In computing the impact of stock option grants, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility of a comparable company; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company cannot assess its forfeiture rate at this time due to the lack of historical data. As of As of Expected volatility 20% to 44% 20% to 44% Expected term 0.08 to 3.08 Years 0.5 to 4.83 Years Risk-Free interest rate 0.05% to 2.49% 0.05% to 2.49% Forfeiture rate 0.00% 0.00% Expected dividend rate 0.00% 0.00% At March 31, 2023, the Company has unvested and vested options under the 2016 Plan with exercise prices that range from a low of $.20 per share to a high of $.51 per share. The following table summarizes information about all of the stock options granted, exercised, expired and cancelled under the 2016 Plan at March 31, 2023 and June 30, 2022: Employees/Consultants Options Wtd. Avg. Wtd. Avg. Aggregate Outstanding at June 30, 2021 16,752,935 $ 0.25 1.76 Years $ - Granted - $ - Expired (5,547,645 ) $ 0.20 Exercised - $ - Cancelled - $ - Outstanding at June 30, 2022 11,205,290 $ 0.30 1.39 Years $ - Granted - $ - Expired (5,000,000 ) $ 0.20 Exercised - $ - Cancelled - $ - Outstanding at March 31, 2023 6,205,290 $ 0.39 1.34 Years $ - The following table summarizes information about vested and unvested options under the 2016 Plan at March 31, 2023 and June 30, 2022. The Company recognized an expense of $60,699 for options vested during the nine months ended March 31, 2023. Employees/Consultants Unvested Vested and Exercisable Total Outstanding at June 30, 2021 2,830,290 13,922,645 16,752,935 Granted - - - Vested and Exercisable (1,235,000 ) 1,235,000 - Cancelled - - - Expired - (5,547,645 ) - Outstanding at June 30, 2022 1,595,290 9,610,000 11,205,290 Granted - - - Vested and Exercisable (500,000 ) 500,000 - Cancelled - - - Expired - (5,000,000 ) - Adjustment - - - Outstanding at March 31, 2023 1,095,290 5,110,000 6,205,290 Unvested options will be expensed under the Black-Scholes options-pricing model when they vest. As of March 31, 2023 remaining options to be expensed when vested over the next year are estimated to be $118,328. At March 31, 2023, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan. All the options for the previous five plans through and including the 2012 Non-Statutory Plan have expired. The tables below summarize information about these five plans: Employees/Consultants Options Wtd. Avg. Wtd. Avg. Aggregate Intrinsic Value Outstanding at June 30, 2021 12 $ 350 1.11 Years $ - Granted - $ - Exercised - $ - Cancelled - $ - Outstanding at June 30, 2022 12 $ 350 0.11 Years $ - Granted - $ - Exercised - $ - Cancelled (12 ) $ 350 Outstanding at March 31, 2023 - $ - - $ - Vested & Exercisable Stock Options March 31, June 30, Employee 2016 Equity Plan - - Director 2016 Equity Plan - - Employee Other Plans - 12 Directors and Consultants Other Plans - - Total - 12 The table below summarizes information about all stock options outstanding as of March 31, 2023: Outstanding Options Vested Options Range of Exercise price Number Weighted Weighted Number Weighted Weighted $0.20 - $0.51 6,205,290 $ 0.39 1.34 5,110,000 $ 0.36 1.05 Total Outstanding options 6,205,290 $ 0.39 1.34 5,110,000 $ 0.36 1.05 The Company’s common stock, symbol IMDS, was quoted on OTCmarkets.com Pink until September 25, 2014 at which time IDSI’s registration was revoked by the Securities and Exchange Commission (SEC) for failure to timely file its Quarterly and Annual Reports. The last quoted price was $0.1. Because the Company was de-registered and OTC markets did not provide a quote for IMDS, there is no public market for the Company’s shares. Given the exercise prices adjusted for the reverse split, it is highly unlikely that any employee holding pre-2016 Plan options will exercise them. The Company has sufficient authorized shares available for all outstanding option; however, if exercised, the shares will be issued with a restrictive legend because the Company was not an SEC reporting company until October 2018. Further, given its recent return to SEC reporting status, the Company is unable to file an S-8 Registration Statement to register shares issued because of option exercise pursuant to various stock option agreements.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	(17) COMMITMENTS AND CONTINGENCIES The Company previously carried $3,000,000 in product liability insurance to cover both clinical sites and sales. As part of its cost savings initiatives, the Company cancelled the policy as it had not had any adverse experiences after conducting more than 25,000 patient scans worldwide. The Company is now self-insuring the risk of product liability. From May 2010 to June 2012, claims were made by the IRS for payment of the Company’s accrued payroll taxes, interest and penalties, which as of June 30, 2012 was $1,489,640. The Company engaged tax counsel to handle this matter and intends to fully satisfy its payroll tax obligations. On August 4, 2014, Viable purchased 250 shares of convertible preferred stock for $2,500,000, which gave them a 78.9% voting and economic interest in the Company’s capital stock representing a change in control of the Company. New management’s tax counsel negotiated a new Installment Agreement which stipulated a lump sum payment of $250,000, which was paid on September 4, 2014 and monthly installment payments of $20,000 beginning in September 2014 due on the 18 th During fiscal 2018, as part of new management’s restructuring plan, the Company received funds from an accredited investor to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting abatement of penalties and interest totaling $314,019. As of March 31, 2023, the Company’s tax counsel is in the process of reviewing recent IRS correspondence to determine appeals status and will work towards final resolutions with the IRS on all outstanding liabilities. The Company has decided to wait until all resolutions are final before making any adjustments to the balance of $314,019 owed to the IRS. On October 23, 2019, the Company entered into a consulting agreement (“the Agreement”) effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focused on improving the technical performance and image quality of IDSI’s CTLM® breast imaging device. Per the Agreement, the goal of the initial project was to complete image quality improvement by November 1, 2020. A payment of $500,000 will be due upon satisfactory completion of the project. As of March 31, 2023, Dr. Jiang has completed the first phase of image quality improvement and is currently collecting image data for evaluation and further technical improvement. We have yet to establish the effectiveness of the improvements, as completion of the project has been delayed due to the COVID-19 crisis.

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	(18) SUBSEQUENT EVENTS On April 5, 2023, the Company received loan proceeds of $1,620 from Erhfort, LLC. Interest is 0% and the principal is payable upon demand.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of presentation and use of estimates	(a) Basis of presentation and use of estimates The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). The unaudited interim financial information furnished herein reflects all adjustments, consisting only of normal recurring items, which in the opinion of management are necessary to fairly state the Company’s financial position, results of operations and cash flows for the dates and periods presented and to make such information not misleading. The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal year ended June 30, 2022, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “Commission”) on October 4, 2022. The results of operations for the nine months ended March 31, 2023, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2023.
Revenue recognition	(b) Revenue recognition As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue. The Company also receives royalties pursuant to a licensing relationship with Trifoil Imaging. Revenue is recognized in the reporting periods in which royalties are due to the Company. During the nine months ended March 31, 2023 and 2022, there was no income from royalties.
Allowance for doubtful accounts	(c) Allowance for doubtful accounts In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience. Our allowance for doubtful accounts was $850 as of March 31, 2023 and June 30, 2022. These amounts consist of other receivables that have been fully reserved.
Cash and cash equivalents	(d) Cash and cash equivalents Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2023 and June 30, 2022.
Concentration of Risk	(e) Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. March 31, 2023 and June 30, 2022, the Company did not have cash balances in excess of the federally insured limit. The Company did not have any revenue for the nine months ended March 31, 2023 and 2022.
Inventory	(f) Inventory Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of obsolete inventory. The Company maintains an allowance for obsolete inventory and generally makes inventory value adjustments against the allowance.
Property and equipment	(g) Property and equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.
Research and development	(h) Research and development Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company’s CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.
Net loss per share	(i) Net loss per share The Company relies on the guidance provided by ASC 260, (“Earnings per Share”), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive. The Company had 5,110,000 and 9,610,012 options vested as of March 31, 2023 and June 30, 2022, respectively and 1,095,290 and 1,595,290 options not yet vested as of March 31, 2023 and June 30, 2022, respectively.
Stock-based compensation	(j) Stock-based compensation In July 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard. The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. No stock options were granted during nine months ended March 31, 2023 and 2022. Stock options are being expensed pursuant to ASC 718. The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (16) Stock Options.
Long-lived assets	(k) Long-lived assets The Company relies on the guidance provided by ASC 360 (“Property, Plant & Equipment”). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized. The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2023 and 2022.
Income taxes	(l) Income taxes The Company accounts for income taxes pursuant to the provisions of ASC 740-10, “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2020 to 2022 are still potentially subject to audit by the taxing authorities.
Warranty reserve	(m) Warranty reserve The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company’s experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company’s estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2023 or June 30, 2022.
Impact of recently issued accounting pronouncements	(n) Impact of recently issued accounting pronouncements Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.
Fair Value of Financial Instruments	(o) Fair Value of Financial Instruments The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company’s debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2023 and June 30, 2022, the aggregate fair value of the Company’s debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 (“Fair Value Measurements and Disclosures”). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Mar. 31, 2023
Inventories [Abstract]
Schedule of inventories	March 31, June 30, Raw materials consisting of purchased parts, components and supplies $ 92,587 $ 92,587 Finished goods 7,500 7,500 Total Inventory $ 100,087 $ 100,087 Allowance for Obsolete Inventory (100,087 ) (100,087 ) Net Inventory $ - $ -

Prepaid Expenses and Deposits (

Prepaid Expenses and Deposits (Tables)	9 Months Ended
	Mar. 31, 2023
Prepaid Expenses and Deposits [Abstract]
Schedule of prepaid expenses	March 31, June 30, Prepaid Software $ - $ 206 Rent Security Deposits 1,783 1,783 Consulting Retainers 10,000 10,000 Total Prepaid expenses and Deposits $ 11,783 $ 11,989

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2023
Property and Equipment [Abstract]
Schedule of property and equipment, less accumulated depreciation	March 31, June 30, Useful life Computers and Equipment $ 12,612 $ 12,612 5 years Third Party Software 10,291 10,291 5 years Clinical Equipment 15,000 15,000 5 years Total Property & Equipment $ 37,903 $ 37,903 Less: accumulated depreciation (37,903 ) (37,903 ) Total Property & Equipment - Net $ - $ -

Promissory Notes _ Related Pa_2

Promissory Notes – Related Party (Tables)	9 Months Ended
	Mar. 31, 2023
Promissory Notes – Related Party [Abstract]
Schedule of outstanding note balances	Noteholder Interest Maturity March 31, June 30, Related Party Notes: Erhfort, LLC 15 % 6/30/23 $ 100,000 $ 100,000 Erhfort, LLC 15 % 6/30/23 100,000 100,000 JM One Holdings, LLC 15 % 6/30/23 20,000 20,000 Erhfort, LLC 15 % 6/30/23 100,000 100,000 Erhfort, LLC 15 % 6/30/23 100,000 100,000 Erhfort, LLC 15 % 6/30/23 100,000 100,000 Erhfort, LLC 15 % 6/30/23 10,000 10,000 Erhfort, LLC 15 % 6/30/23 10,000 10,000 Erhfort, LLC 0 % On Demand 2,260 - Erhfort, LLC 0 % On Demand 3,669 - Viable International Investments, LLC 0 % On Demand 7,865 7,865 Viable International Investments, LLC 0 % On Demand 5,000 5,000 Viable International Investments, LLC 0 % On Demand 5,000 5,000 Viable International Investments, LLC 0 % On Demand 5,000 5,000 Viable International Investments, LLC 0 % On Demand 5,000 5,000 Viable International Investments, LLC 0 % On Demand 3,000 3,000 Viable International Investments, LLC 0 % On Demand 15,000 15,000 Viable International Investments, LLC 0 % On Demand 30,000 30,000 Viable International Investments, LLC 0 % On Demand 10,000 10,000 Viable International Investments, LLC 0 % On Demand 10,000 10,000 Viable International Investments, LLC 0 % On Demand 10,000 10,000 Viable International Investments, LLC 0 % On Demand 5,000 5,000 Viable International Investments, LLC 0 % On Demand 10,000 10,000 Viable International Investments, LLC 0 % On Demand 8,847 - Viable International Investments, LLC 0 % On Demand 12,768 - Viable International Investments, LLC 0 % On Demand 9,988 - Viable International Investments, LLC 0 % On Demand 7,968 - Viable International Investments, LLC 0 % On Demand 6,968 - Viable International Investments, LLC 0 % On Demand 7,786 - Viable International Investments, LLC 0 % On Demand 5,368 - Viable International Investments, LLC 0 % On Demand 5,488 - Viable International Investments, LLC 0 % On Demand 11,568 - Xi’an IDI 0 % On Demand 10,411 10,411 Total Related Party Notes $ 753,954 $ 671,276

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Mar. 31, 2023
Long-Term Debt [Abstract]
Schedule of a summary of the outstanding loan balances	Noteholder Interest Maturity March 31, June 30, Truist Bank 1 % In Default $ 72,930 $ 72,930 Total Debt 72,930 72,930 Current Portion of Debt (72,930 ) (72,930 ) Total Long-term Debt $ - $ -

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	9 Months Ended
	Mar. 31, 2023
Convertible Preferred Stock [Abstract]
Schedule of number of shares of preferred stock that have been issued, converted and are outstanding	Security Date Issued No. of Amount Date of No. of Amount Balance Series L Cv Pfd 3/31/2010 35 $ 350,000 1/6/2011 15 $ 150,000 $ 200,000 Dividends 247,451 Total redemption value $ 447,451 Total Series M Cv Pfd Various 600 $ 6,000,000 1/6/2011 600 $ 6,000,000 $ -0- Dividends -0- Total redemption value $ -0-

Stock Options (Tables)

Stock Options (Tables)	9 Months Ended
	Mar. 31, 2023
Stock Options [Abstract]
Schedule of estimate the expected forfeiture rate and only recognize expense	As of As of Expected volatility 20% to 44% 20% to 44% Expected term 0.08 to 3.08 Years 0.5 to 4.83 Years Risk-Free interest rate 0.05% to 2.49% 0.05% to 2.49% Forfeiture rate 0.00% 0.00% Expected dividend rate 0.00% 0.00%
Schedule of stock options granted, exercised, expired and cancelled	Employees/Consultants Options Wtd. Avg. Wtd. Avg. Aggregate Outstanding at June 30, 2021 16,752,935 $ 0.25 1.76 Years $ - Granted - $ - Expired (5,547,645 ) $ 0.20 Exercised - $ - Cancelled - $ - Outstanding at June 30, 2022 11,205,290 $ 0.30 1.39 Years $ - Granted - $ - Expired (5,000,000 ) $ 0.20 Exercised - $ - Cancelled - $ - Outstanding at March 31, 2023 6,205,290 $ 0.39 1.34 Years $ - Employees/Consultants Options Wtd. Avg. Wtd. Avg. Aggregate Intrinsic Value Outstanding at June 30, 2021 12 $ 350 1.11 Years $ - Granted - $ - Exercised - $ - Cancelled - $ - Outstanding at June 30, 2022 12 $ 350 0.11 Years $ - Granted - $ - Exercised - $ - Cancelled (12 ) $ 350 Outstanding at March 31, 2023 - $ - - $ -
Schedule of vested and unvested options	Employees/Consultants Unvested Vested and Exercisable Total Outstanding at June 30, 2021 2,830,290 13,922,645 16,752,935 Granted - - - Vested and Exercisable (1,235,000 ) 1,235,000 - Cancelled - - - Expired - (5,547,645 ) - Outstanding at June 30, 2022 1,595,290 9,610,000 11,205,290 Granted - - - Vested and Exercisable (500,000 ) 500,000 - Cancelled - - - Expired - (5,000,000 ) - Adjustment - - - Outstanding at March 31, 2023 1,095,290 5,110,000 6,205,290
Schedule of information about vested & exercisable stock options	Vested & Exercisable Stock Options March 31, June 30, Employee 2016 Equity Plan - - Director 2016 Equity Plan - - Employee Other Plans - 12 Directors and Consultants Other Plans - - Total - 12
Schedule of stock options outstanding	Outstanding Options Vested Options Range of Exercise price Number Weighted Weighted Number Weighted Weighted $0.20 - $0.51 6,205,290 $ 0.39 1.34 5,110,000 $ 0.36 1.05 Total Outstanding options 6,205,290 $ 0.39 1.34 5,110,000 $ 0.36 1.05

Going Concern and Management'_2

Going Concern and Management's Plans (Details)	9 Months Ended
	Mar. 31, 2023 USD ($)
Going Concern and Management's Plans [Abstract]
Accumulated deficit	$ 135,784,184
Stockholders’ deficit	2,487,368
Working capital deficit	2,039,917
Net loss	287,676
Net cash used in operating activities	$ 79,499

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Accounting Policies [Abstract]
Allowance for doubtful accounts (in Dollars)	$ 850	$ 850
Federal deposit insurance corporation limit (in Dollars)	$ 250,000
Options vested	5,110,000	9,610,012
Options non vested	1,095,290	1,595,290
Tax position, description	Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority.

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended	9 Months Ended
	Mar. 22, 2018	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Related Party Transactions (Details) [Line Items]
Contract term	20 years
Percentage of transfer fee	25%
Accounts payable		$ 2,808		$ 839
Short-Term Debt		753,954		671,276
Ehrfort, LLC [Member]
Related Party Transactions (Details) [Line Items]
Consulting fee		51,000	$ 76,500
Accounts payable		219,814		161,260
David Fong [Member]
Related Party Transactions (Details) [Line Items]
Consulting fee		32,545	$ 76,500
Erhfort, LLC One [Member]
Related Party Transactions (Details) [Line Items]
Accounts payable		204,000		153,000
Fong & Associates, LLC [Member]
Related Party Transactions (Details) [Line Items]
Accounts payable and accrued expense		318,545		286,000
JM One Holdings, LLC [Member]
Related Party Transactions (Details) [Line Items]
Accrued expenses		$ 11,112		$ 8,860

Royalty Receivable (Details)

Royalty Receivable (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Royalty Receivable [Abstract]
Royalty receivable balances	$ 0	$ 0

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventories - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Schedule of inventories [Abstract]
Raw materials consisting of purchased parts, components and supplies	$ 92,587	$ 92,587
Finished goods	7,500	7,500
Total Inventory	100,087	100,087
Allowance for Obsolete Inventory	(100,087)	(100,087)
Net Inventory

Prepaid Expenses and Deposits_2

Prepaid Expenses and Deposits (Details) - Schedule of prepaid expenses - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Prepaid Expenses and Deposits [Abstract]
Prepaid Software		$ 206
Rent Security Deposits	1,783	1,783
Consulting Retainers	10,000	10,000
Total Prepaid expenses and Deposits	$ 11,783	$ 11,989

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0	$ 0

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment, less accumulated depreciation - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Property, Plant and Equipment [Line Items]
Total Property & Equipment	$ 37,903	$ 37,903
Less: accumulated depreciation	(37,903)	(37,903)
Total Property & Equipment - Net
Computers and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property & Equipment	$ 12,612	12,612
Useful life	5 years
Third Party Software [Member]
Property, Plant and Equipment [Line Items]
Total Property & Equipment	$ 10,291	10,291
Useful life	5 years
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property & Equipment	$ 15,000	$ 15,000
Useful life	5 years

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable and accrued expenses	$ 910,920	$ 767,317
Accounts payable	898,468	758,171
Other accrued expenses	$ 12,452	$ 9,146

Accrued Payroll Taxes and Pen_2

Accrued Payroll Taxes and Penalties (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022	Jun. 27, 2018
Accrued Payroll Taxes and Penalties [Abstract]
Accrued payroll taxes	$ 314,019	$ 314,019
Balance of taxes due			$ 381,224
Interest and penalties	314,019
Remaining interest and penalties	314,019
Adjustments balance	$ 314,019

Promissory Notes _ Related Pa_3

Promissory Notes – Related Party (Details) - USD ($)		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Promissory Notes – Related Party (Details) [Line Items]
Annual interest rate, percentage		0%
Accounts payables	$ 898,468	$ 898,468		$ 758,171
Promissory notes related party, description	the maturity dates of the loans that were due to mature on March 31, 2023 were extended to June 30, 2023.
Viable International Investments, LLC [Member]
Promissory Notes – Related Party (Details) [Line Items]
Loan proceeds			$ 80,000
Annual interest rate, percentage			0%
Viable International Investments, LLC [Member]
Promissory Notes – Related Party (Details) [Line Items]
Loan proceeds		76,749
Related parties amount		$ 2,260
Annual interest rate, percentage		0%
Accounts payables	$ 3,669	$ 3,669

Promissory Notes _ Related Pa_4

Promissory Notes – Related Party (Details) - Schedule of outstanding note balances - USD ($)	9 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Promissory Notes – Related Party [Abstract]
Total Related Party Notes	$ 753,954	$ 671,276
Erhfort, LLC [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	15%
Maturity Date	6/30/23
Total Related Party Notes	$ 100,000	100,000
Erhfort, LLC One [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	15%
Maturity Date	6/30/23
Total Related Party Notes	$ 100,000	100,000
JM One Holdings, LLC [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	15%
Maturity Date	6/30/23
Total Related Party Notes	$ 20,000	20,000
Erhfort, LLC Two [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	15%
Maturity Date	6/30/23
Total Related Party Notes	$ 100,000	100,000
Erhfort, LLC Three [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	15%
Maturity Date	6/30/23
Total Related Party Notes	$ 100,000	100,000
Erhfort, LLC Four [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	15%
Maturity Date	6/30/23
Total Related Party Notes	$ 100,000	100,000
Erhfort, LLC Five [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	15%
Maturity Date	6/30/23
Total Related Party Notes	$ 10,000	10,000
Erhfort, LLC Six [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	15%
Maturity Date	6/30/23
Total Related Party Notes	$ 10,000	10,000
Erhfort, LLC Seven [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 2,260
Erhfort, LLC Eight [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 3,669
Viable International Investments, LLC [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 7,865	7,865
Viable International Investments, LLC One [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 5,000	5,000
Viable International Investments, LLC Two [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 5,000	5,000
Viable International Investments, LLC Three [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 5,000	5,000
Viable International Investments, LLC Four [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 5,000	5,000
Viable International Investments, LLC Five [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 3,000	3,000
Viable International Investments, LLC Six [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 15,000	15,000
Viable International Investments, LLC Seven [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 30,000	30,000
Viable International Investments, LLC Eight [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 10,000	10,000
Viable International Investments, LLC Nine [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 10,000	10,000
Viable International Investments, LLC Ten [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 10,000	10,000
Viable International Investments, LLC Eleven [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 5,000	5,000
Viable International Investments, LLC Twelve [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 10,000	10,000
Viable International Investments, LLC Thirteen [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 8,847
Viable International Investments, LLC Fourteen [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 12,768
Viable International Investments, LLC Fifteen [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 9,988
Viable International Investments, LLC Sixteen [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 7,968
Viable International Investments, LLC Seventeen [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 6,968
Viable International Investments, LLC Eighteen [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 7,786
Viable International Investments, LLC Nineteen [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 5,368
Viable International Investments, LLC Twenty [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 5,488
Viable International Investments, LLC Twenty One [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 11,568
Xi’an IDI [Member]
Promissory Notes – Related Party [Abstract]
Interest Rate	0%
Maturity Date	On Demand
Total Related Party Notes	$ 10,411	$ 10,411

Long-Term Debt (Details)

Long-Term Debt (Details) - USD ($)		1 Months Ended	9 Months Ended	12 Months Ended
	May 09, 2020	Oct. 31, 2021	Mar. 31, 2023	Jun. 30, 2022
Long-Term Debt (Details) [Line Items]
Loan amount	$ 79,600
Maturity date	May 01, 2025
Interest rate		1%
PPP Loan [Member]
Long-Term Debt (Details) [Line Items]
Accrued interest			$ 740	$ 186

Long-Term Debt (Details) - Sche

Long-Term Debt (Details) - Schedule of a summary of the outstanding loan balances - USD ($)	9 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Debt Instrument [Line Items]
Total Debt	$ 72,930	$ 72,930
Current Portion of Debt	(72,930)	(72,930)
Total Long-term Debt
Truist Bank [Member]
Debt Instrument [Line Items]
Interest Rate	1%
Maturity Date	In Default
Total Debt	$ 72,930	$ 72,930

Convertible Preferred Stock (De

Convertible Preferred Stock (Details) - USD ($)			1 Months Ended			9 Months Ended
	Aug. 07, 2018	Jan. 06, 2011	Nov. 21, 2017	Apr. 18, 2017	Mar. 31, 2010	Mar. 31, 2023	Jun. 30, 2022
Convertible Preferred Stock (Details) [Line Items]
Redemption value (in Dollars)						$ 247,450	$ 233,939
Total temporary equity (in Dollars)						$ 447,451	$ 433,939
Series L Convertible Preferred Stock [Member]
Convertible Preferred Stock (Details) [Line Items]
Converted short term promissory note (in Dollars)					$ 350,000
Convertible preferred stock					35
Original purchase price (in Dollars)					$ 10,000
Annual rate					9%
Conversion of preferred stock to common stock					474
Convertible preferred stock description		On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time.
Series M Preferred Stock [Member]
Convertible Preferred Stock (Details) [Line Items]
Convertible preferred stock						147,283
Original purchase price (in Dollars)						$ 10,000
Conversion of preferred stock to common stock	591		3	6
Convertible preferred stock						600
Other equity securities (in Dollars per share)						$ 10,000
Cumulative dividend fixed rate						9%
Shares of restricted common stock	87,044,089		441,878	883,696
Preferred stock, shares issued						0	0

Convertible Preferred Stock (_2

Convertible Preferred Stock (Details) - Schedule of number of shares of preferred stock that have been issued, converted and are outstanding	9 Months Ended
	Mar. 31, 2023 USD ($) shares
Series L Cv Pfd [Member]
Convertible Preferred Stock [Abstract]
Dividends	$ 247,451
Total redemption value	$ 447,451
Series L Cv Pfd [Member] | Issued on 3/31/2010 [Member]
Convertible Preferred Stock [Abstract]
No. of Shares (in Shares) | shares	35
Amount	$ 350,000
Date of Conversion	Jan. 06, 2011
No. of Shares Converted (in Shares) | shares	15
Amount Converted	$ 150,000
Balance 12/31/2022	$ 200,000
Series M Cv Pfd [Member]
Convertible Preferred Stock [Abstract]
No. of Shares (in Shares) | shares	600
Amount	$ 6,000,000
Date of Conversion	Jan. 06, 2011
No. of Shares Converted (in Shares) | shares	600
Amount Converted	$ 6,000,000
Balance 12/31/2022	0
Dividends	0
Total redemption value	$ 0

Common Stock (Details)

Common Stock (Details) - $ / shares	Mar. 31, 2023	Jun. 30, 2022
Common Stock [Abstract]
Common stock, shares authorized	500,000,000	500,000,000
Preferred stock, shares authorized	2,000,000	2,000,000
Common stock, no par value
Preferred stock, no par value

Stock Options (Details)

Stock Options (Details)	9 Months Ended
	Mar. 31, 2023 USD ($) $ / shares
Stock Options [Abstract]
Lower range of exercise price	$ 0.20
Purchase exercise price	$ 0.51
Expense of options vested (in Dollars) | $	$ 60,699
Estimated vesting expense (in Dollars) | $	$ 118,328
Stock options, description	At March 31, 2023, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan.
Shares issued, price per share	$ 0.1

Stock Options (Details) - Sched

Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense [Line Items]
Forfeiture rate	0%	0%
Expected dividend rate	0%	0%
Minimum [Member]
Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense [Line Items]
Expected volatility	20%	20%
Expected term	29 days	6 months
Risk-Free interest rate	0.05%	0.05%
Maximum [Member]
Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense [Line Items]
Expected volatility	44%	44%
Expected term	3 years 29 days	4 years 9 months 29 days
Risk-Free interest rate	2.49%	2.49%

Stock Options (Details) - Sch_2

Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Vested and Unvested Options [Member]
Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled [Line Items]
Options, Outstanding	11,205,290	16,752,935
Wtd. Avg. Exercise Price, Outstanding	$ 0.3	$ 0.25
Wtd. Avg. Remaining Term, Outstanding		1 year 9 months 3 days
Aggregate Intrinsic Value, Outstanding
Options, Granted
GrantedWtd. Avg. Exercise Price, Granted
Options, Expired	(5,000,000)	(5,547,645)
Wtd. Avg. Exercise Price, Expired	$ 0.2	$ 0.2
Options, Exercised
Wtd. Avg. Exercise Price, Exercised
Aggregate Intrinsic Value, Exercised
Options, Cancelled
Wtd. Avg. Exercise Price, Cancelled
Aggregate Intrinsic Value, Cancelled
Options, Outstanding	6,205,290	11,205,290
Wtd. Avg. Exercise Price, Outstanding	$ 0.39	$ 0.3
Wtd. Avg. Remaining Term, Outstanding	1 year 4 months 2 days	1 year 4 months 20 days
Aggregate Intrinsic Value, Outstanding
Previous Five Plan Including Non-Statutory Plan [Member]
Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled [Line Items]
Options, Outstanding	12	12
Wtd. Avg. Exercise Price, Outstanding	$ 350	$ 350
Wtd. Avg. Remaining Term, Outstanding		1 year 1 month 9 days
Aggregate Intrinsic Value, Outstanding
Options, Granted
GrantedWtd. Avg. Exercise Price, Granted
Options, Exercised
Wtd. Avg. Exercise Price, Exercised
Options, Cancelled	(12)
Wtd. Avg. Exercise Price, Cancelled	$ 350
Aggregate Intrinsic Value, Cancelled
Options, Outstanding		12
Wtd. Avg. Exercise Price, Outstanding		$ 350
Wtd. Avg. Remaining Term, Outstanding		1 month 9 days
Aggregate Intrinsic Value, Outstanding

Stock Options (Details) - Sch_3

Stock Options (Details) - Schedule of vested and unvested options - shares	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Stock Options (Details) - Schedule of vested and unvested options [Line Items]
Outstanding, beginning balance	11,205,290	16,752,935
Granted
Vested and Exercisable
Cancelled
Expired
Adjustment
Outstanding, ending balance	6,205,290	11,205,290
Unvested [Member]
Stock Options (Details) - Schedule of vested and unvested options [Line Items]
Outstanding, beginning balance	1,595,290	2,830,290
Granted
Vested and Exercisable	(500,000)	(1,235,000)
Cancelled
Expired
Adjustment
Outstanding, ending balance	1,095,290	1,595,290
Vested and Exercisable [Member]
Stock Options (Details) - Schedule of vested and unvested options [Line Items]
Outstanding, beginning balance	9,610,000	13,922,645
Granted
Vested and Exercisable	500,000	1,235,000
Cancelled
Expired	(5,000,000)	(5,547,645)
Adjustment
Outstanding, ending balance	5,110,000	9,610,000

Stock Options (Details) - Sch_4

Stock Options (Details) - Schedule of information about vested & exercisable stock options - shares	Mar. 31, 2023	Jun. 30, 2022
Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]
Vested & Exercisable Stock Options, Total		12
Employee 2016 Equity Plan [Member]
Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]
Vested & Exercisable Stock Options, Total
Director 2016 Equity Plan [Member]
Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]
Vested & Exercisable Stock Options, Total
Employee Other Plans [Member]
Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]
Vested & Exercisable Stock Options, Total		12
Directors and Consultants Other Plans [Member]
Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]
Vested & Exercisable Stock Options, Total

Stock Options (Details) - Sch_5

Stock Options (Details) - Schedule of stock options outstanding	9 Months Ended
	Mar. 31, 2023 $ / shares shares
Outstanding Options [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of outstanding | shares	6,205,290
Weighted Averaged Exercise Price | $ / shares	$ 0.39
Weighted Averaged Remaining Life (Years)	1 year 4 months 2 days
Vested Options [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Weighted Averaged Exercise Price | $ / shares	$ 0.36
Weighted Averaged Remaining Life (Years)	1 year 18 days
Number of Exercisable | shares	5,110,000
$0.20 - $0.51 [Member] | Outstanding Options [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of outstanding | shares	6,205,290
Weighted Averaged Exercise Price | $ / shares	$ 0.39
Weighted Averaged Remaining Life (Years)	1 year 4 months 2 days
$0.20 - $0.51 [Member] | Vested Options [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Weighted Averaged Exercise Price | $ / shares	$ 0.36
Weighted Averaged Remaining Life (Years)	1 year 18 days
Number of Exercisable | shares	5,110,000

Commitments and Contingencies (

Commitments and Contingencies (Details)		9 Months Ended
	Aug. 04, 2014 USD ($) shares	Mar. 31, 2023 USD ($)	Jun. 29, 2018 USD ($)	Jun. 27, 2018 USD ($)	Sep. 04, 2014 USD ($)	Apr. 04, 2014 USD ($)	Jun. 30, 2012 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Product liability insurance		$ 3,000,000
Number of patients		25,000
Accrued payroll taxes, interest and penalties							$ 1,489,640
Purchase of convertible preferred stock (in Shares) | shares	250
Convertible preferred stock value	$ 2,500,000
Voting and economic interest percentage	78.90%
Lump sum payment					$ 250,000
Monthly installment payments						$ 20,000
Balance of taxes due				$ 381,224
Penalties and interest totaling			$ 314,019
Balance owed adjustments		$ 314,019
Payment of satisfactory completion		$ 500,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	Apr. 05, 2023 USD ($)
Subsequent Events (Details) [Line Items]
Interest percentage	0%
Erhfort, LLC [Member]
Subsequent Events (Details) [Line Items]
Loan proceeds	$ 1,620